These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 25914777)

  • 21. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease.
    Papagianni M; Sofogianni A; Tziomalos K
    World J Hepatol; 2015 Apr; 7(4):638-48. PubMed ID: 25866601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?
    Ajmera V; Loomba R
    Semin Liver Dis; 2018 Feb; 38(1):14-20. PubMed ID: 29471562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Dharmalingam M; Yamasandhi PG
    Indian J Endocrinol Metab; 2018; 22(3):421-428. PubMed ID: 30090738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
    Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver disease.
    Isabela Andronescu C; Roxana Purcarea M; Aurel Babes P
    J Med Life; 2018; 11(3):243-246. PubMed ID: 30364513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can gadoxetic acid-enhanced magnetic resonance imaging be used to avoid liver biopsy in patients with nonalcoholic fatty liver disease?
    Amorim VB; Parente DB; Paiva FF; Oliveira Neto JA; Miranda AA; Moreira CC; Fernandes FF; Campos CFF; Leite NC; Perez RM; Rodrigues RS
    World J Hepatol; 2020 Sep; 12(9):661-671. PubMed ID: 33033571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
    Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
    J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Caussy C; Johansson L
    Endocrinol Diabetes Metab; 2020 Oct; 3(4):e00134. PubMed ID: 33102797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?
    Singh SP; Barik RK
    J Clin Exp Hepatol; 2020; 10(1):88-98. PubMed ID: 32025168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic steatohepatitis recurrence after liver transplant.
    Taneja S; Roy A
    Transl Gastroenterol Hepatol; 2020; 5():24. PubMed ID: 32258528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).
    Han MA; Saouaf R; Ayoub W; Todo T; Mena E; Noureddin M
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):379-390. PubMed ID: 28277807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.
    Tiniakos DG
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):643-50. PubMed ID: 19478676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
    Agrawal S; Duseja A
    Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
    Kaswala DH; Lai M; Afdhal NH
    Dig Dis Sci; 2016 May; 61(5):1356-64. PubMed ID: 27017224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD.
    Alkhouri N; McCullough AJ
    Gastroenterol Hepatol (N Y); 2012 Oct; 8(10):661-8. PubMed ID: 24683373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathology of nonalcoholic steatohepatitis.
    Brunt EM
    Hepatol Res; 2005 Oct; 33(2):68-71. PubMed ID: 16214395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ultrasonography in the diagnosis of nonalcoholic fatty liver disease].
    Gomercić M; Duvnjak M; Barsić N
    Acta Med Croatica; 2009 Dec; 63 Suppl 3():1-3. PubMed ID: 20235368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts.
    Mayo R; Crespo J; Martínez-Arranz I; Banales JM; Arias M; Mincholé I; Aller de la Fuente R; Jimenez-Agüero R; Alonso C; de Luis DA; Vitek L; Stritesky J; Caballería J; Romero-Gómez M; Martín-Duce A; Mugüerza Huguet JM; Busteros-Moraza JI; Idowu MO; Castro A; Martínez-Chantar ML; Ortiz P; Bruha R; Lu SC; Bedossa P; Noureddin M; Sanyal AJ; Mato JM
    Hepatol Commun; 2018 Jul; 2(7):807-820. PubMed ID: 30027139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.